Journal
PEDIATRIC NEPHROLOGY
Volume 31, Issue 4, Pages 633-640Publisher
SPRINGER
DOI: 10.1007/s00467-015-3249-5
Keywords
Anti-interleukin 1; Autoinflammatory disease; Renal amyloidosis; Proteinuria; Anakinra
Categories
Funding
- Novartis
- Sobi
Ask authors/readers for more resources
Background Amyloidosis may complicate autoinflammatory diseases (AID). We aimed to evaluate the renal biopsy findings, and clinical and laboratory parameters in patients with AID-associated amyloidosis who have responded to antiinterleukin 1(IL1) treatment. Methods Two children with systemic juvenile idiopathic arthritis and one with cryopyrin-associated periodic syndrome diagnosed as having reactive amyloidosis were treated with anti-IL1 drugs. The renal histopathological findings at the time of diagnosis of amyloidosis and after the onset of antiIL1 were evaluated according to the amyloid scoring/grading system. Results The median age of disease onset and diagnosis of amyloidosis were 3 and 12 years, respectively. Anakinra was started in all; however, anakinra caused a local cutaneous reaction in one, thus canakinumab was commenced. Proteinuria improved in all. Control renal biopsies were performed a median of 3 years after the first biopsies. The renal amyloid prognostic score did not improve in patient 1, and progressed in patients 2 and 3. The renal amyloid grade progressed in patient 2. Conclusions This is the first series demonstrating progression of renal tissue damage after the improvement of proteinuria with anti-IL 1 in AID-associated amyloidosis. Anti-IL1 drugs are important to prevent further amyloid accumulation; however, new treatment strategies are needed to target the amyloid deposits.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available